Anavex Life Sciences Corp. (AVXL) Financials
AVXL Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 148.1 million | 12.5 million |
2023-09-30 | 154.4 million | 12.5 million |
2023-06-30 | 157.8 million | 11.1 million |
2023-03-31 | 159.2 million | 14.0 million |
AVXL Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -7.3 million | 2.3 million |
2023-09-30 | -5.8 million | 3.2 million |
2023-06-30 | -7.7 million | 3.9 million |
2023-03-31 | -8.5 million | 4.0 million |
AVXL Net Income
No data available :(
AVXL Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 143.8 million | - | - |
2023-09-30 | 151.0 million | - | - |
2023-06-30 | 154.8 million | - | - |
2023-03-31 | 153.5 million | - | - |
AVXL Shares Outstanding
AVXL Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | - | 8.7 million | 2.6 million | - |
2023-09-30 | - | 10.1 million | 2.6 million | - |
2023-06-30 | - | 10.3 million | 3.2 million | - |
2023-03-31 | - | 11.3 million | 2.9 million | - |
AVXL Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | - | - |
2023-09-30 | - | - |
2023-06-30 | - | - |
2023-03-31 | - | - |
AVXL
Price: $3.79
52 week price:
Earnings Per Share: -0.54 USD
P/E Ratio: -9.09
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.1 million
Ebitda: -4.1 millionMarket Capitalization: 316.1 million